GlassScriptPhysician profile
Elizabeth Curtis
NPI 1215934377
$1,750.80
in general payments reported to CMS, 2019-2025
19 companies · $99.15 in 2025
The $99.15 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $281 · 2021: $551 · 2022: $245 · 2023: $114 · 2024: $160 · 2025: $99.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $496.41 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $205.24 | 2021-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $138.65 | 2023-2024 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $125.00 | 2019 | |
| Vifor Pharma, INC. | $122.80 | 2020 | |
| Silk Road Medical, INC. | $120.62 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $119.12 | 2021-2023 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $73.09 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $70.40 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.81 | 2019-2025 | Austedo Xr, Austedo Xr |
| Urovant Sciences INC | $41.85 | 2021-2022 | |
| Pfizer INC. | $33.40 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $33.14 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $31.90 | 2021-2023 | Mounjaro, Trulicity |
| Lundbeck LLC | $26.54 | 2023 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.87 | 2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $17.74 | 2024 | Voquezna |
| Cmp Pharma, INC. | $14.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.